

CADTH RAPID RESPONSE REPORT: REFERENCE LIST

Dissolution Techniques for Buprenorphine and Buprenorphine-Naloxone: Clinical Effectiveness and Guidelines

Service Line:	Rapid Response Service
Version:	1.0
Publication Date:	September 23, 2019
Report Length:	5 Pages

Authors: Christopher Freige, Charlene Argáez

Cite As: Dissolution techniques for Buprenorphine and Buprenorphine-Naloxone: clinical effectiveness and guidelines. Ottawa: CADTH; 2019 Sep. (CADTH rapid response report: reference list).

Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein do not necessarily reflect the views of Health Canada, Canada's provincial or territorial governments, other CADTH funders, or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian *Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

Questions or requests for information about this report can be directed to requests@cadth.ca

Research Questions

1. What is the comparative clinical effectiveness of sublingual buprenorphine tablets administered using dissolution practices versus standard administration of buprenorphine for the treatment of opioid use disorder or dependency?
2. What is the comparative clinical effectiveness of sublingual buprenorphine-naloxone tablets administered using dissolution practices versus standard administration of these drugs for the treatment of opioid use disorder or dependency?
3. What are the evidence-based guidelines regarding the dissolution of buprenorphine or buprenorphine-naloxone combination tablets for the treatment of opioid use disorder or dependency?

Key Findings

No literature was identified regarding the comparative clinical effectiveness of sublingual buprenorphine or buprenorphine-naloxone tablets administered using dissolution practices versus standard administration for the treatment of opioid use disorder or dependency. Furthermore, no evidence-based guidelines were identified regarding the dissolution of buprenorphine or buprenorphine-naloxone combination tablets for the treatment of opioid use disorder or dependency.

Methods

This report makes use of a literature search developed for a previous CADTH report. The original literature search was conducted in June 2016 on key resources including PubMed, The Cochrane Library, University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. The search strategy was comprised of both controlled vocabulary, such as the National Library of Medicine’s MeSH (Medical Subject Headings), and keywords. The main search concepts were buprenorphine and forms of administration. No filters were applied to limit the retrieval by study type. Where possible, retrieval was limited to the human population. The initial search was also limited to English-language documents published between January 1, 2011 and June 16, 2016. For the current report, database searches were rerun on September 17, 2019 to capture any articles published since the initial search date. The search of major health technology agencies was also updated to include documents published since June 2016. Internet links are provided, where available.

Selection Criteria

One reviewer screened citations and selected studies based on the inclusion criteria presented in Table 1.

Table 1: Selection Criteria

Population	Adults with opioid dependency, opioid use disorder, or substance use disorder
Interventions	Q1, Q3: Sublingual buprenorphine tablets administered using dissolution practices (e.g., crushing, mixing with saliva) Q2, Q3: Sublingual buprenorphine-naloxone combination tablets administered using dissolution practices
Comparators	Q1: Standard administration of sublingual buprenorphine tablets

	Q2: Standard administration of sublingual buprenorphine-naloxone tablets Q3: No comparator necessary
Outcomes	Q1-2: Clinical effectiveness (e.g., patient satisfaction, time to dissolution, opiate withdrawal symptoms [e.g., clinical opioid withdrawal score], safety [e.g., adverse reactions]) Q3: Evidence-based guidelines
Study Designs	Health technology assessments, systematic reviews, meta-analyses, randomized controlled trials, non-randomized studies, evidence-based guidelines

Results

Rapid Response reports are organized so that the higher quality evidence is presented first. Therefore, health technology assessment reports, systematic reviews, and meta-analyses are presented first. These are followed by randomized controlled trials, non-randomized studies, and evidence-based guidelines.

No literature was identified regarding the comparative clinical effectiveness of sublingual buprenorphine or buprenorphine-naloxone tablets administered using dissolution practices versus standard administration for the treatment of opioid use disorder or dependency. Furthermore, no evidence-based guidelines were identified regarding the dissolution of buprenorphine or buprenorphine-naloxone combination tablets for the treatment of opioid use disorder or dependency.

References of potential interest are provided in the appendix.

Health Technology Assessments

No literature identified.

Systematic Reviews and Meta-analyses

No literature identified.

Randomized Controlled Trials

No literature identified.

Non-Randomized Studies

No literature identified.

Guidelines and Recommendations

No literature identified.

Appendix — Further Information

Previous CADTH Reports

1. Marchand DK, Young C, Loshak H. Buprenorphine for opioid use disorder: a review of comparative clinical effectiveness, safety, cost-effectiveness, and guidelines (*CADTH rapid response report: summary with critical appraisal*). Ottawa (ON): CADTH; 2019 Apr;
<https://www.cadth.ca/sites/default/files/pdf/htis/2019/RC1092%20Buprenorphine%20for%20OUD%20Final.pdf>
 Accessed 2019 Sep 23.
2. Seal K, Argáez C. Buprenorphine formulations for the treatment of opioid use disorders: comparative clinical effectiveness, cost-effectiveness, and guidelines (*CADTH rapid response report: reference list*). Ottawa (ON): CADTH; 2018 Apr;
<https://www.cadth.ca/sites/default/files/pdf/htis/2018/RA0951%20Buprenorphine%20Formulations%20Update%20Final.pdf>
 Accessed 2019 Sep 23.
3. CADTH. Crushed Buprenorphine or Buprenorphine-Naloxone for opioid dependency: a review of the clinical effectiveness and guidelines (*CADTH rapid response report: summary with critical appraisal*). Ottawa (ON): CADTH; 2016 Jul;
<https://www.cadth.ca/sites/default/files/pdf/htis/july-2016/RC0794-Crushed%20Suboxone%20Final.pdf>
 Accessed 2019 Sep 23.

Systematic Reviews and Meta-analyses

4. Lagisetty P, Klasa K, Bush C, et al. Primary care models for treating opioid use disorders: what actually works? A systematic review. *PLoSOne*. 2017; 12(10):e0186315.
[PubMed: PM29040331](https://pubmed.ncbi.nlm.nih.gov/29040331/)

Non-Randomized Studies

Published Outside of the Literature Search Time Frame

5. Muhleisen P, Nielsen S, Spence J, Lintzeris N. Crushing sublingual Buprenorphinenaloxone tablets: impact upon dissolution time for supervised dispensing. *Aust Pharm*. 2010 Feb;29(2):158-162.
<https://search.informit.com.au/documentSummary;dn=059179298330064;res=IELAPA>
 Accessed 2019 Sep 23.